Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lesson Learned

<< Previous

Bullboard Posts

Next >>

Comment by Sikongon Feb 17, 2021 11:47pm

183 Views

Post# 32592854

RE:RE:RE:RE:RE:RE:Lesson Learned

RjM2018 wrote: The thought crossed my mind that this could be a raise to buy IP from Antibe holdings...

With the Nuance deal we had enough to fund the phase 3 alone which is around $30 million. This allows us to fund pre-IND work for 2 other molecules which is really exciting! By the time we finish phase 3 we could have 2 other molecules ready for IND submission which would increase the amount we command.

I have the same guess too. Time will tell.

<< Previous

Bullboard Posts

Next >>

Three mispriced stocks exposed to major market tailwinds